Standout Papers
Citation Impact
Citing Papers
The discovery and development of HMG-CoA reductase inhibitors.
1992
Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials
2010
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
1992 Standout
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)
2010
Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk
2009
Effects of Combination Lipid Therapy on Coronary Stenosis Progression and Clinical Cardiovascular Events in Coronary Disease Patients With Metabolic Syndrome: A Combined Analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS)
2009
Mechanisms linking obesity with cardiovascular disease
2006 StandoutNature
Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile
2014 StandoutNature
By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
1994
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
1995 Standout
A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis
1995 Standout
Hallmarks of aging: An expanding universe
2023 Standout
Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis
2006
Cholesterol reduction and its impact on coronary artery disease and total mortality
1995
Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2.
1997
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction
1992 StandoutNature
Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease
2001
Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients
1994
Bile acid sequestrants
2011
ESDN, a Novel Neuropilin-like Membrane Protein Cloned from Vascular Cells with the Longest Secretory Signal Sequence among Eukaryotes, Is Up-regulated after Vascular Injury
2001 StandoutNobel
Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity
2002
Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein
1997 StandoutNature
Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events
2001
Rationale and design of the Department of Veterans Affairs high-density lipoprotein cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol
1993
Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk
2010
DANCE, a Novel Secreted RGD Protein Expressed in Developing, Atherosclerotic, and Balloon-injured Arteries
1999 StandoutNobel
Combined therapy in the treatment of dyslipidemia
2009
Suppression of Niacin-induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1
2007
Lipid-lowering interventions in angiographic trials
1995
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients
2014
The L-Arginine-Nitric Oxide Pathway
1993 Standout
Mortality over a Period of 10 Years in Patients with Peripheral Arterial Disease
1992 Standout
The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover
1993
Niacin in cardiovascular prevention: mechanisms, efficacy, and safety
2007
Composition and classification of human atherosclerotic lesions
1992
NAD+ homeostasis in health and disease
2020
Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Coadministered With Extended-Release Niacin in Patients With Type IIa or Type IIb Hyperlipidemia
2008
Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk
2003 Standout
Comparison of an Immunoprecipitation Method for Direct Measurement of LDL-Cholesterol With Beta-Quantification (Ultracentrifugation)
1995
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
1996 Standout
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
2000 Standout
Atherosclerosis — An Inflammatory Disease
1999 Standout
Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease
2009 Standout
Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials
2012
Carotid-Artery Intima and Media Thickness as a Risk Factor for Myocardial Infarction and Stroke in Older Adults
1999 Standout
β-Arrestin1 mediates nicotinic acid–induced flushing, but not its antilipolytic effect, in mice
2009 StandoutNobel
The influence of pretreatment lew density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials
1995
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
1999 Standout
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
2005 Standout
Biochemistry and molecular cell biology of diabetic complications
2001 StandoutNature
Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events
1995
Lipoprotein(a) as a cardiovascular risk factor: current status
2010
Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
2009
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
Effect of Pravastatin on Outcomes after Cardiac Transplantation
1995 Standout
Tomographic imaging using the nonlinear response of magnetic particles
2005 StandoutNature
National Cholesterol Education Program's recommendations, and implications of “missing” high-density lipoprotein cholesterol in cardiac rehabilitation programs
1991
Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk?
2004
A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis
1995 Standout
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
Inflammation, Atherosclerosis, and Coronary Artery Disease
2005 Standout
Atherosclerosis
2000 StandoutNature
Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men
1997 Standout
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
2008 Standout
Elastin is an essential determinant of arterial morphogenesis
1998 StandoutNature
Nicotinic Acid, Alone and in Combinations, for Reduction of Cardiovascular Risk
2008
Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
1999
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
2004 Standout
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
2010 StandoutNature
Atherosclerosis
2001 Standout
The pathogenesis of atherosclerosis: a perspective for the 1990s
1993 StandoutNature
Enhanced atherosclerosis and kidney dysfunction in eNOS–/–Apoe–/– mice are ameliorated by enalapril treatment
2000 StandoutNobel
Range of serum cholesterol values in the population developing coronary artery disease
1995
Association between Multiple Cardiovascular Risk Factors and Atherosclerosis in Children and Young Adults
1998 Standout
Advances in Coronary Angioplasty
1996
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
2005 Standout
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Report of the Conference on Low Blood Cholesterol: Mortality Associations.
1992
The Coronary Angiogram and Its Seminal Contributions to Cardiovascular Medicine Over Five Decades
2002
Functional Arteries Grown in Vitro
1999 StandoutScience
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
1998 Standout
Total Synthesis of α-Pyrone Meroterpenoids, Novel Bioactive Microbial Metabolites
2005 StandoutNobel
Rous-Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry.
1993
Simvastatin Reduces Graft Vessel Disease and Mortality After Heart Transplantation
1997
MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis
1991 Standout
Kuopio Atherosclerosis Prevention Study (KAPS)
1995
Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease.
1993
Niacin Accelerates Intracellular ApoB Degradation by Inhibiting Triacylglycerol Synthesis in Human Hepatoblastoma (HepG2) Cells
1999
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
2011
Requirement for Generation of H 2 O 2 for Platelet-Derived Growth Factor Signal Transduction
1995 StandoutScience
Aggressive Cholesterol Lowering Delays Saphenous Vein Graft Atherosclerosis in Women, the Elderly, and Patients With Associated Risk Factors
1999
Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content.
1993 Standout
Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol Levels
1995
Niacin Decreases Removal of High-Density Lipoprotein Apolipoprotein A-I But Not Cholesterol Ester by Hep G2 Cells
1997
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
1994
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)
1994
Atherosclerosis--reversal with therapy.
1993
Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound.
1993
Beneficial Effect of Carotid Endarterectomy in Symptomatic Patients with High-Grade Carotid Stenosis
1991 Standout
Cholesterol Reduction Yields Clinical Benefit
1998
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
2004 Standout
Gene targeting approaches to complex genetic diseases: atherosclerosis and essential hypertension.
1995 StandoutNobel
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
2002 Standout
Cholesterol Reduction Yields Clinical Benefit
1995
The Intima
1995
Cost and health implications of cholesterol lowering.
1992
Works of Brad Bisson being referenced
Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B
1990 Standout
Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B.
1993
A maximum confidence strategy for measuring progression and regression of coronary artery disease in clinical trials
1993